APO Research
Talk to an analyst

APO RESEARCH · REPORT

Natural Killer Cell Therapy

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Explore the product
View pricing & licenses

Product & engineering

Understand the product.

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

Selected research

Market Analysis & Forecast

Global Natural Killer Cell Therapy Market Analysis and Forecast 2026-2032

31 December 2025193 pages

Choose your research edition.

Industry ResearchNatural Killer Cell Therapy Industry Research Report 2026124 pages · $2,950 USDIndustry Growth & TrendsGlobal Natural Killer Cell Therapy Industry Growth and Trends Forecast to 2032104 pages · $3,450 USDMarket StructureGlobal Natural Killer Cell Therapy Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Natural Killer Cell Therapy Market Outlook and Growth Opportunities 2026191 pages · $4,250 USDMarket Analysis & ForecastGlobal Natural Killer Cell Therapy Market Analysis and Forecast 2026-2032193 pages · $4,950 USD

Market perspective

Cell therapy, a new therapeutic approach that uses a patient's own immune cells to attack tumors, has emerged as one of the most promising breakthroughs in cancer treatment. NK cells are the body's first line of defense against infections and diseases with an innate ability to rapidly seek and destroy abnormal cells.

The Americas natural killer cells therapeutics market share accounted for the highest share 52.3% in 2019.

Based on application, the market is classified into cancer, gastrointestinal diseases and others. The cancer segment accounted for a major share in 2019 (66.99%).

Read the full market overview

Major players operating in the market include Nektar Therapeutics, Innate Pharma SA, Affimed, Chipscreen Biosciences, Fate Therapeutics, Glycostem Therapeutics, Dragonfly Therapeutics, Kiadis Pharma, NantWorks, Nkarta Therapeutics and etc. The Top 6 players accounted for 96.66% of the global revenue market share in 2019.

Report Includes

This report presents an overview of global market for Natural Killer Cell Therapy, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Natural Killer Cell Therapy, also provides the revenue of main regions and countries. Of the upcoming market potential for Natural Killer Cell Therapy, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Natural Killer Cell Therapy revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Natural Killer Cell Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Natural Killer Cell Therapy revenue, projected growth trends, production technology, application and end-user industry.

Natural Killer Cell Therapy Segment by Company

Nektar Therapeutics

Innate Pharma SA

Affimed

Chipscreen Biosciences

Glycostem Therapeutics

Fate Therapeutics

Dragonfly Therapeutics

Kiadis Pharma

Nkarta Therapeutics

NantKwest

Natural Killer Cell Therapy Segment by Type

NK Cell Therapies

NK Cell Directed Antibodies

Natural Killer Cell Therapy Segment by Application

Cancer

Gastrointestinal Diseases

Others

Natural Killer Cell Therapy Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Natural Killer Cell Therapy market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Natural Killer Cell Therapy and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Natural Killer Cell Therapy.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Natural Killer Cell Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Natural Killer Cell Therapy company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Natural Killer Cell Therapy revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Natural Killer Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. NK Cell Therapies Major Player Table 3. NK Cell Directed Antibodies Major Player Table 4. Global Natural Killer Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Cancer Major Player Table 6. Gastrointestinal Diseases Major Player Table 7. Others Major Player Table 8. Natural Killer Cell Therapy Industry Trends Table 9. Natural Killer Cell Therapy Industry Drivers Table 10. Natural Killer Cell Therapy Industry Opportunities and Challenges Table 11. Natural Killer Cell Therapy Industry Restraints Table 12. Global Natural Killer Cell Therapy Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Natural Killer Cell Therapy Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Natural Killer Cell Therapy Market Share by Region (2021-2026) Table 15. Global Natural Killer Cell Therapy Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Natural Killer Cell Therapy Market Share by Region (2027-2032) Table 17. Global Natural Killer Cell Therapy Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Natural Killer Cell Therapy Revenue Market Share by Players (2021-2026) Table 19. Global Natural Killer Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Natural Killer Cell Therapy Key Players Headquarters & Area Served Table 21. Global Natural Killer Cell Therapy Players, Product Type & Application Table 22. Global Natural Killer Cell Therapy Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Natural Killer Cell Therapy by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Natural Killer Cell Therapy Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Natural Killer Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Natural Killer Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Natural Killer Cell Therapy Revenue Market Share by Type (2021-2026) Table 29. Global Natural Killer Cell Therapy Revenue Market Share by Type (2027-2032) Table 30. Global Natural Killer Cell Therapy Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Natural Killer Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Natural Killer Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Natural Killer Cell Therapy Revenue Market Share by Application (2021-2026) Table 34. Global Natural Killer Cell Therapy Revenue Market Share by Application (2027-2032) Table 35. Nektar Therapeutics Company Information Table 36. Nektar Therapeutics Business Overview Table 37. Nektar Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Nektar Therapeutics Natural Killer Cell Therapy Product Portfolio Table 39. Nektar Therapeutics Recent Development Table 40. Innate Pharma SA Company Information Table 41. Innate Pharma SA Business Overview Table 42. Innate Pharma SA Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Innate Pharma SA Natural Killer Cell Therapy Product Portfolio Table 44. Innate Pharma SA Recent Development Table 45. Affimed Company Information Table 46. Affimed Business Overview Table 47. Affimed Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Affimed Natural Killer Cell Therapy Product Portfolio Table 49. Affimed Recent Development Table 50. Chipscreen Biosciences Company Information Table 51. Chipscreen Biosciences Business Overview Table 52. Chipscreen Biosciences Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Chipscreen Biosciences Natural Killer Cell Therapy Product Portfolio Table 54. Chipscreen Biosciences Recent Development Table 55. Glycostem Therapeutics Company Information Table 56. Glycostem Therapeutics Business Overview Table 57. Glycostem Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Glycostem Therapeutics Natural Killer Cell Therapy Product Portfolio Table 59. Glycostem Therapeutics Recent Development Table 60. Fate Therapeutics Company Information Table 61. Fate Therapeutics Business Overview Table 62. Fate Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. Fate Therapeutics Natural Killer Cell Therapy Product Portfolio Table 64. Fate Therapeutics Recent Development Table 65. Dragonfly Therapeutics Company Information Table 66. Dragonfly Therapeutics Business Overview Table 67. Dragonfly Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Dragonfly Therapeutics Natural Killer Cell Therapy Product Portfolio Table 69. Dragonfly Therapeutics Recent Development Table 70. Kiadis Pharma Company Information Table 71. Kiadis Pharma Business Overview Table 72. Kiadis Pharma Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Kiadis Pharma Natural Killer Cell Therapy Product Portfolio Table 74. Kiadis Pharma Recent Development Table 75. Nkarta Therapeutics Company Information Table 76. Nkarta Therapeutics Business Overview Table 77. Nkarta Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Nkarta Therapeutics Natural Killer Cell Therapy Product Portfolio Table 79. Nkarta Therapeutics Recent Development Table 80. NantKwest Company Information Table 81. NantKwest Business Overview Table 82. NantKwest Natural Killer Cell Therapy Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. NantKwest Natural Killer Cell Therapy Product Portfolio Table 84. NantKwest Recent Development Table 85. North America Natural Killer Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 86. North America Natural Killer Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 87. North America Natural Killer Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 88. North America Natural Killer Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 89. North America Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 90. North America Natural Killer Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 91. North America Natural Killer Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 92. Europe Natural Killer Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 93. Europe Natural Killer Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 94. Europe Natural Killer Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 95. Europe Natural Killer Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 96. Europe Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 97. Europe Natural Killer Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 98. Europe Natural Killer Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 99. China Natural Killer Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 100. China Natural Killer Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 101. China Natural Killer Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 102. China Natural Killer Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 103. Asia Natural Killer Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 104. Asia Natural Killer Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 105. Asia Natural Killer Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 106. Asia Natural Killer Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 107. Asia Natural Killer Cell Therapy Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 108. Asia Natural Killer Cell Therapy Revenue by Region (US$ Million) & (2021-2026) Table 109. Asia Natural Killer Cell Therapy Revenue by Region (US$ Million) & (2027-2032) Table 110. SAMEA Natural Killer Cell Therapy Revenue by Type (2021-2026) & (US$ Million) Table 111. SAMEA Natural Killer Cell Therapy Revenue by Type (2027-2032) & (US$ Million) Table 112. SAMEA Natural Killer Cell Therapy Revenue by Application (2021-2026) & (US$ Million) Table 113. SAMEA Natural Killer Cell Therapy Revenue by Application (2027-2032) & (US$ Million) Table 114. SAMEA Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 115. SAMEA Natural Killer Cell Therapy Revenue by Country (2021-2026) & (US$ Million) Table 116. SAMEA Natural Killer Cell Therapy Revenue by Country (US$ Million) & (2027-2032) Table 117. Research Programs/Design for This Report Table 118. Authors List of This Report Table 119. Secondary Sources Table 120. Primary Sources List of Figures Figure 1. Natural Killer Cell Therapy Image Figure 2. Global Natural Killer Cell Therapy Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Natural Killer Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 4. NK Cell Therapies Image Figure 5. NK Cell Directed Antibodies Image Figure 6. Global Natural Killer Cell Therapy Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Natural Killer Cell Therapy Market Size Share 2021 VS 2025 VS 2032 Figure 8. Cancer Image Figure 9. Gastrointestinal Diseases Image Figure 10. Others Image Figure 11. Global Natural Killer Cell Therapy Market Size (US$ Million) & (2021-2032) Figure 12. Global Natural Killer Cell Therapy Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Natural Killer Cell Therapy Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Natural Killer Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Natural Killer Cell Therapy Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Natural Killer Cell Therapy Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Natural Killer Cell Therapy Revenue Market Share by Type (2021-2032) Figure 19. Global Natural Killer Cell Therapy Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Natural Killer Cell Therapy Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Natural Killer Cell Therapy Revenue Market Share by Application (2021-2032) Figure 22. North America Natural Killer Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Natural Killer Cell Therapy Revenue Share by Type (2021-2032) Figure 24. North America Natural Killer Cell Therapy Revenue Share by Application (2021-2032) Figure 25. North America Natural Killer Cell Therapy Revenue Share by Country (2021-2032) Figure 26. United States Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Natural Killer Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Natural Killer Cell Therapy Revenue Share by Type (2021-2032) Figure 31. Europe Natural Killer Cell Therapy Revenue Share by Application (2021-2032) Figure 32. Europe Natural Killer Cell Therapy Revenue Share by Country (2021-2032) Figure 33. Germany Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Natural Killer Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Natural Killer Cell Therapy Revenue Share by Type (2021-2032) Figure 43. China Natural Killer Cell Therapy Revenue Share by Application (2021-2032) Figure 44. Asia Natural Killer Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Natural Killer Cell Therapy Revenue Share by Type (2021-2032) Figure 46. Asia Natural Killer Cell Therapy Revenue Share by Application (2021-2032) Figure 47. Asia Natural Killer Cell Therapy Revenue Share by Region (2021-2032) Figure 48. Japan Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Natural Killer Cell Therapy Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Natural Killer Cell Therapy Revenue Share by Type (2021-2032) Figure 56. SAMEA Natural Killer Cell Therapy Revenue Share by Application (2021-2032) Figure 57. SAMEA Natural Killer Cell Therapy Revenue Share by Country (2021-2032) Figure 58. Brazil Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Natural Killer Cell Therapy Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • NK Cell Therapies
  • NK Cell Directed Antibodies
Applications
  • Cancer
  • Gastrointestinal Diseases
  • Others
Companies covered
  • Nektar Therapeutics
  • Innate Pharma SA
  • Affimed
  • Chipscreen Biosciences
  • Glycostem Therapeutics
  • Fate Therapeutics
  • Dragonfly Therapeutics
  • Kiadis Pharma
  • Nkarta Therapeutics
  • NantKwest

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Natural Killer Cell Therapy Market by Type
  3. 1.2.1 Global Natural Killer Cell Therapy Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 NK Cell Therapies
  5. 1.2.3 NK Cell Directed Antibodies
  6. 1.3 Natural Killer Cell Therapy Market by Application
  7. 1.3.1 Global Natural Killer Cell Therapy Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Cancer
  9. 1.3.3 Gastrointestinal Diseases
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Natural Killer Cell Therapy Market Dynamics
  1. 2.1 Natural Killer Cell Therapy Industry Trends
  2. 2.2 Natural Killer Cell Therapy Industry Drivers
  3. 2.3 Natural Killer Cell Therapy Industry Opportunities and Challenges
  4. 2.4 Natural Killer Cell Therapy Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Natural Killer Cell Therapy Market Perspective (2021-2032)
  2. 3.2 Global Natural Killer Cell Therapy Growth Trends by Region
  3. 3.2.1 Global Natural Killer Cell Therapy Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Natural Killer Cell Therapy Market Size by Region (2021-2026)
  5. 3.2.3 Global Natural Killer Cell Therapy Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Natural Killer Cell Therapy Revenue by Players
  2. 4.1.1 Global Natural Killer Cell Therapy Revenue by Players (2021-2026)
  3. 4.1.2 Global Natural Killer Cell Therapy Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Natural Killer Cell Therapy Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Natural Killer Cell Therapy Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Natural Killer Cell Therapy Key Players Headquarters & Area Served
  7. 4.4 Global Natural Killer Cell Therapy Players, Product Type & Application
  8. 4.5 Global Natural Killer Cell Therapy Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Natural Killer Cell Therapy Market CR5 and HHI
  11. 4.6.3 2025 Natural Killer Cell Therapy Tier 1, Tier 2, and Tier 3
5 Natural Killer Cell Therapy Market Size by Type
  1. 5.1 Global Natural Killer Cell Therapy Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Natural Killer Cell Therapy Revenue by Type (2021-2032)
  3. 5.3 Global Natural Killer Cell Therapy Revenue Market Share by Type (2021-2032)
6 Natural Killer Cell Therapy Market Size by Application
  1. 6.1 Global Natural Killer Cell Therapy Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Natural Killer Cell Therapy Revenue by Application (2021-2032)
  3. 6.3 Global Natural Killer Cell Therapy Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Nektar Therapeutics
  2. 7.1.1 Nektar Therapeutics Company Information
  3. 7.1.2 Nektar Therapeutics Business Overview
  4. 7.1.3 Nektar Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Nektar Therapeutics Natural Killer Cell Therapy Product Portfolio
  6. 7.1.5 Nektar Therapeutics Recent Developments
  7. 7.2 Innate Pharma SA
  8. 7.2.1 Innate Pharma SA Company Information
  9. 7.2.2 Innate Pharma SA Business Overview
  10. 7.2.3 Innate Pharma SA Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Innate Pharma SA Natural Killer Cell Therapy Product Portfolio
  12. 7.2.5 Innate Pharma SA Recent Developments
  13. 7.3 Affimed
  14. 7.3.1 Affimed Company Information
  15. 7.3.2 Affimed Business Overview
  16. 7.3.3 Affimed Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Affimed Natural Killer Cell Therapy Product Portfolio
  18. 7.3.5 Affimed Recent Developments
  19. 7.4 Chipscreen Biosciences
  20. 7.4.1 Chipscreen Biosciences Company Information
  21. 7.4.2 Chipscreen Biosciences Business Overview
  22. 7.4.3 Chipscreen Biosciences Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Chipscreen Biosciences Natural Killer Cell Therapy Product Portfolio
  24. 7.4.5 Chipscreen Biosciences Recent Developments
  25. 7.5 Glycostem Therapeutics
  26. 7.5.1 Glycostem Therapeutics Company Information
  27. 7.5.2 Glycostem Therapeutics Business Overview
  28. 7.5.3 Glycostem Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Glycostem Therapeutics Natural Killer Cell Therapy Product Portfolio
  30. 7.5.5 Glycostem Therapeutics Recent Developments
  31. 7.6 Fate Therapeutics
  32. 7.6.1 Fate Therapeutics Company Information
  33. 7.6.2 Fate Therapeutics Business Overview
  34. 7.6.3 Fate Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  35. 7.6.4 Fate Therapeutics Natural Killer Cell Therapy Product Portfolio
  36. 7.6.5 Fate Therapeutics Recent Developments
  37. 7.7 Dragonfly Therapeutics
  38. 7.7.1 Dragonfly Therapeutics Company Information
  39. 7.7.2 Dragonfly Therapeutics Business Overview
  40. 7.7.3 Dragonfly Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Dragonfly Therapeutics Natural Killer Cell Therapy Product Portfolio
  42. 7.7.5 Dragonfly Therapeutics Recent Developments
  43. 7.8 Kiadis Pharma
  44. 7.8.1 Kiadis Pharma Company Information
  45. 7.8.2 Kiadis Pharma Business Overview
  46. 7.8.3 Kiadis Pharma Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Kiadis Pharma Natural Killer Cell Therapy Product Portfolio
  48. 7.8.5 Kiadis Pharma Recent Developments
  49. 7.9 Nkarta Therapeutics
  50. 7.9.1 Nkarta Therapeutics Company Information
  51. 7.9.2 Nkarta Therapeutics Business Overview
  52. 7.9.3 Nkarta Therapeutics Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Nkarta Therapeutics Natural Killer Cell Therapy Product Portfolio
  54. 7.9.5 Nkarta Therapeutics Recent Developments
  55. 7.10 NantKwest
  56. 7.10.1 NantKwest Company Information
  57. 7.10.2 NantKwest Business Overview
  58. 7.10.3 NantKwest Natural Killer Cell Therapy Revenue and Gross Margin (2021-2026)
  59. 7.10.4 NantKwest Natural Killer Cell Therapy Product Portfolio
  60. 7.10.5 NantKwest Recent Developments
8 North America
  1. 8.1 North America Natural Killer Cell Therapy Revenue (2021-2032)
  2. 8.2 North America Natural Killer Cell Therapy Revenue by Type (2021-2032)
  3. 8.2.1 North America Natural Killer Cell Therapy Revenue by Type (2021-2026)
  4. 8.2.2 North America Natural Killer Cell Therapy Revenue by Type (2027-2032)
  5. 8.3 North America Natural Killer Cell Therapy Revenue Share by Type (2021-2032)
  6. 8.4 North America Natural Killer Cell Therapy Revenue by Application (2021-2032)
  7. 8.4.1 North America Natural Killer Cell Therapy Revenue by Application (2021-2026)
  8. 8.4.2 North America Natural Killer Cell Therapy Revenue by Application (2027-2032)
  9. 8.5 North America Natural Killer Cell Therapy Revenue Share by Application (2021-2032)
  10. 8.6 North America Natural Killer Cell Therapy Revenue by Country
  11. 8.6.1 North America Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Natural Killer Cell Therapy Revenue by Country (2021-2026)
  13. 8.6.3 North America Natural Killer Cell Therapy Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
  16. 8.6.6 Mexico
9 Europe
  1. 9.1 Europe Natural Killer Cell Therapy Revenue (2021-2032)
  2. 9.2 Europe Natural Killer Cell Therapy Revenue by Type (2021-2032)
  3. 9.2.1 Europe Natural Killer Cell Therapy Revenue by Type (2021-2026)
  4. 9.2.2 Europe Natural Killer Cell Therapy Revenue by Type (2027-2032)
  5. 9.3 Europe Natural Killer Cell Therapy Revenue Share by Type (2021-2032)
  6. 9.4 Europe Natural Killer Cell Therapy Revenue by Application (2021-2032)
  7. 9.4.1 Europe Natural Killer Cell Therapy Revenue by Application (2021-2026)
  8. 9.4.2 Europe Natural Killer Cell Therapy Revenue by Application (2027-2032)
  9. 9.5 Europe Natural Killer Cell Therapy Revenue Share by Application (2021-2032)
  10. 9.6 Europe Natural Killer Cell Therapy Revenue by Country
  11. 9.6.1 Europe Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Natural Killer Cell Therapy Revenue by Country (2021-2026)
  13. 9.6.3 Europe Natural Killer Cell Therapy Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Russia
  19. 9.6.9 Spain
  20. 9.6.10 Netherlands
  21. 9.6.11 Switzerland
  22. 9.6.12 Sweden
  23. 9.6.13 Poland
10 China
  1. 10.1 China Natural Killer Cell Therapy Revenue (2021-2032)
  2. 10.2 China Natural Killer Cell Therapy Revenue by Type (2021-2032)
  3. 10.2.1 China Natural Killer Cell Therapy Revenue by Type (2021-2026)
  4. 10.2.2 China Natural Killer Cell Therapy Revenue by Type (2027-2032)
  5. 10.3 China Natural Killer Cell Therapy Revenue Share by Type (2021-2032)
  6. 10.4 China Natural Killer Cell Therapy Revenue by Application (2021-2032)
  7. 10.4.1 China Natural Killer Cell Therapy Revenue by Application (2021-2026)
  8. 10.4.2 China Natural Killer Cell Therapy Revenue by Application (2027-2032)
  9. 10.5 China Natural Killer Cell Therapy Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Natural Killer Cell Therapy Revenue (2021-2032)
  2. 11.2 Asia Natural Killer Cell Therapy Revenue by Type (2021-2032)
  3. 11.2.1 Asia Natural Killer Cell Therapy Revenue by Type (2021-2026)
  4. 11.2.2 Asia Natural Killer Cell Therapy Revenue by Type (2027-2032)
  5. 11.3 Asia Natural Killer Cell Therapy Revenue Share by Type (2021-2032)
  6. 11.4 Asia Natural Killer Cell Therapy Revenue by Application (2021-2032)
  7. 11.4.1 Asia Natural Killer Cell Therapy Revenue by Application (2021-2026)
  8. 11.4.2 Asia Natural Killer Cell Therapy Revenue by Application (2027-2032)
  9. 11.5 Asia Natural Killer Cell Therapy Revenue Share by Application (2021-2032)
  10. 11.6 Asia Natural Killer Cell Therapy Revenue by Country
  11. 11.6.1 Asia Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Natural Killer Cell Therapy Revenue by Country (2021-2026)
  13. 11.6.3 Asia Natural Killer Cell Therapy Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Natural Killer Cell Therapy Revenue (2021-2032)
  2. 12.2 SAMEA Natural Killer Cell Therapy Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Natural Killer Cell Therapy Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Natural Killer Cell Therapy Revenue by Type (2027-2032)
  5. 12.3 SAMEA Natural Killer Cell Therapy Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Natural Killer Cell Therapy Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Natural Killer Cell Therapy Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Natural Killer Cell Therapy Revenue by Application (2027-2032)
  9. 12.5 SAMEA Natural Killer Cell Therapy Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Natural Killer Cell Therapy Revenue by Country
  11. 12.6.1 SAMEA Natural Killer Cell Therapy Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Natural Killer Cell Therapy Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Natural Killer Cell Therapy Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst